Swedish biotech innovator Cellevate has secured SEK 21.3 million (approximately €2 million / $2.3 million) in fresh funding to accelerate the commercialization of its nanofiber-based cell culture technology for biopharmaceutical production.
Reinventing How Biologics Are Manufactured
Founded in Lund in 2014, Cellevate develops advanced nanofiber materials designed to improve how cells are grown in the production of biological drugs and vaccines.
At the core of its innovation is its proprietary platform, Cellevat3d, which enables seamless scaling from laboratory environments to industrial biomanufacturing. This is a critical breakthrough in a sector where low yields and high production costs remain major bottlenecks.
By increasing efficiency and simplifying scale-up, Cellevate’s technology has the potential to make advanced therapies more accessible to patients worldwide.
Backed by Leading Nordic Investors
The funding round was led by Almi Invest, which contributed SEK 3 million, alongside angel investors and existing backers including Industrifonden and the EIC Fund.
This mix of public and private capital highlights continued confidence in Cellevate’s scalable technology and its relevance in the rapidly growing biopharma market.
According to Karsten Fjärstedt, the strong participation from both existing and new investors reflects trust in the company’s strategy and its ability to bring its technology to market.
From Lab Innovation to Industrial Adoption
Cellevate is no longer just a research-driven company—it has already launched products and is now entering a key commercialization phase. Customers, primarily in biologics and vaccine manufacturing, are beginning to integrate the technology into real-world production workflows.
The company’s solutions are designed to work across the entire production chain—from early-stage research to full-scale manufacturing—ensuring consistency, reproducibility, and efficiency.
Importantly, Cellevate operates under ISO 9001:2015 certification and has implemented GMP (Good Manufacturing Practice) processes in cleanroom environments, aligning with strict industry standards required for pharmaceutical production.
Why This Matters
Biopharmaceutical manufacturing is under increasing pressure to deliver more—faster and at lower cost. Whether for cell and gene therapies or next-generation vaccines, scalable and efficient production technologies are essential.
Cellevate is positioning itself as a key enabler in this space, addressing one of the industry’s most persistent challenges: how to reliably scale complex biological processes without compromising quality.
As Anna Gisselsson noted, the company is entering a phase where its products directly meet market demand—making this a pivotal moment for growth and adoption.
What’s Next
With fresh funding secured, Cellevate will focus on expanding customer adoption, strengthening its commercial presence, and continuing to refine its technology platform.
As the demand for biologics and advanced therapies accelerates globally, Cellevate’s nanofiber-based approach could play a crucial role in shaping the future of biomanufacturing.
